Johnson & Johnson
JNJ.SW News Today: Stay Updated with the Latest Johnson & Johnson News in Real Time
Find JNJ.SW news now at Meyka AI. Stay informed with the latest Johnson & Johnson stocks updates, including price news, market analysis, and expert insights.
Morgan Stanley maintains Overweight on Johnson & Johnson (JNJ) March 2026
JNJ analyst rating: Morgan Stanley maintained Overweight on JNJ on March 18, 2026 after expected Ico approval
Jefferies Maintains Buy on Protagonist Therapeutics (PTGX) PT $121 Mar 2026
PTGX analyst rating update: Jefferies, Johnson Rice maintain Buy; PT $121 and royalty model cited
Centessa Shares Soar Following Lilly’s $6.3B Acquisition Announcement
The stock market reacted strongly after a major acquisition announcement involving Centessa Shares. Eli Lilly, one of the largest pharmaceutical companies in the world, confirmed it will acquire Centessa Pharmaceuticals for $6.3 billion in an all‑cash deal. This news caused Centessa Shares to surge sharply, making the acquisition one of the most talked‑about deals in…
Google Launches TurboQuant AI Memory Compression algorithm, Dubbed ‘Pied Piper’ Online
On March 25, 2026, Google introduced TurboQuant, a new AI memory compression algorithm that is already making headlines across the tech world. Early reports show it can cut AI memory use by at least six times while keeping accuracy unchanged. Even more impressive, it may boost performance by up to 8x in some cases. The…
Morgan Stanley Maintains Overweight on Johnson & Johnson JNJ March 18, 2026
Morgan Stanley keeps Overweight on Johnson & Johnson; JNJ analyst rating, market impact and Meyka AI grade B+ explained
Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) March 2026
PTGX analyst rating: Jefferies and Johnson Rice maintain Buy March 2026 with price target updates and market context
Morgan Stanley Maintains Overweight on Johnson & Johnson (JNJ) March 18, 2026
JNJ analyst rating: Morgan Stanley maintains Overweight on Johnson & Johnson on March 18, 2026
Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) Mar 2026
PTGX analyst rating: Jefferies and Johnson Rice maintain Buy; Jefferies raises PT to $121 Mar 18, 2026
Morgan Stanley Maintains Positive on Pfizer Inc. (PFE) March 2026
Morgan Stanley maintained positive on Pfizer; analysis of PFE analyst rating, market impact, and Meyka AI grade B+